Salbutamol, Pharmacogenetics and Breathing Mechanics
This trial has been completed.
|Conditions||bronchoconstriction, inhaled salbutamol, cycling performance|
|Sponsor||University of British Columbia|
|Collaborator||World Anti-Doping Agency (WADA)|
|Start date||May 2013|
|End date||December 2014|
|Trial size||94 participants|
|Trial identifier||NCT01903785, H09-01154-A009|
Athletes using asthma medications called β2-agonists win a disproportionately high number of medals at Olympic Games. Due to a large variety in the genes that affect how individuals respond to β2-agonists, the investigators will look at variations in the genetic response to these medications by dividing athletes into high-responders and low-responders. The investigators will then compare athletic performance after the inhalation of β2-agonists to placebo. Furthermore, the investigators will analyze the effect of β2-agonists on breathing mechanics. Due to differences in their anatomy females may decrease the energy needed for breathing during high-intensity exercise to a greater extent compared to male athletes after the inhalation of β2-agonists.
|Endpoint classification||pharmacodynamics study|
|Intervention model||crossover assignment|
|Masking||double blind (subject, investigator)|
|Primary purpose||basic science|
The effect of inhaled salbutamol on mean power output during cycling performance in female and male athletes
time frame: Mean power output is assessed over the duration of a 10km time trial (start of time trial until completion of time trial) on a bike ergometer.
The effect of inhaled salbutamol on work of breathing (WOB) and expiratory flow limitation (EFL) in female and male athletes
time frame: WOB and EFL will be assessed during an incremental exercise test. Exercise will start at 0 Watts and will then be increased every 2.5min by 30 Watts until maximal exertion.
The effect of inhaled salbutamol on minute ventilation in asthmatic and non-asthmatic trained, female and male cyclists
time frame: Minute ventilation will be assessed during two 10km time trials (one time trial will be started 60min after the inhalation of salbutamol, the second time trial will be started 60min after the inhalation of placebo).
Male or female participants from 19 years up to 45 years old.
- trained, experienced cyclists
- maximal oxygen consumption of at least 50ml/kg/min or 4l/min for women; and 60ml/kg/min or 5l/min for men
- athletes with and without exercise-induced bronchoconstriction
- any uncontrolled heart or lung condition
- maximal oxygen consumption of less than 50ml/kg/min or 4L/min for women; and less than 60ml/kg/min or 5L/min for men
|Official title||The Pharmacogenetic Effects of Inhaled Salbutamol on Breathing Mechanics and Cycling Performance|
|Principal investigator||Michael S Koehle, MD, PhD|
Call for more information